GILEAD SCIENCES, INC. $500,000,000 1.950% SENIOR NOTES DUE 2022 $750,000,000 2.500% SENIOR NOTES DUE 2023 $1,250,000,000 2.950% SENIOR NOTES DUE 2027 $750,000,000 4.000% SENIOR NOTES DUE 2036 $1,750,000,000 4.150% SENIOR NOTES DUE 2047 Underwriting...Underwriting Agreement • September 20th, 2016 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
The Securities will be issued pursuant to an Indenture dated as of March 30, 2011 (the “Base Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by a supplemental indenture to be dated as of September 20, 2016 (together with the Base Indenture, the “Indenture”).
